title: A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
abstract: The conventional dose of deprenyl used in Parkinson's disease is 10 mg/day, having been established by in vitro platelet studies and clinical evaluation. Twelve patients with Parkinson's disease on treatment with L-dopa who showed evidence of wearing-off effects or motor oscillation were studied in a double-blind, placebo-controlled, crossover trial to compare conventional doses of deprenyl with higher doses (up to 40 mg/day) and placebo. We did not find higher doses of deprenyl to be superior to conventional doses and in 17% of cases treatment had to be withdrawn because of side effects.
authors.affiliation: Department of Neurology, University College and Middlesex Hospitals, School of Medicine, London, U.K.
authors.forename: J P
authors.initials: JP
authors.lastname: Frankel
authors.forename: P A
authors.initials: PA
authors.lastname: Kempster
authors.forename: C M
authors.initials: CM
authors.lastname: Stibe
authors.forename: V M
authors.initials: VM
authors.lastname: Eatough
authors.forename: M
authors.initials: M
authors.lastname: Nathanson
authors.forename: A J
authors.initials: AJ
authors.lastname: Lees
authors.forename: G M
authors.initials: GM
authors.lastname: Stern
mesh_terms: D000277:Adjuvants, Pharmaceutic; D000368:Aged; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000008:administration & dosage*; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000277:Adjuvants, Pharmaceutic; D010627:Phenethylamines; D012642:Selegiline; D007980:Levodopa